Abbott Laboratories (NYSE: ABT ) markets everything from Similac baby formula to cataract surgery equipment and its restructuring itself in order to spark revenue growth.
Abbott is a long-standing member of the S&P 500 dividend aristocrats, a collection of companies with a proud history of dividend increases, so investors are right to wonder if sluggish sales tied to a recall last fall are ready to rebound.
In the following slideshow, I include the most important takeaways from Abbott's second-quarter results and highlight the key reasons Abbott may find the second half of this year is better than the first.
Even Abbott may struggle to outperform these top dividend stocks over the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.